<DOC>
	<DOCNO>NCT01314027</DOCNO>
	<brief_summary>The outcome patient resect pancreatic cancer significantly improve adjuvant chemotherapy . However , large proportion patient receive adjuvant chemotherapy due surgical complication . Neoadjuvant chemotherapy show safe effective apply patient . This study test neoadjuvant chemotherapy randomize manner . Patients resectable cytologically proven adenocarinoma pancreatic head randomize arm A B . Patients randomize arm A receive 8-week neoadjuvant chemotherapy gemcitabine/oxaliplatin follow surgery . Thereafter , patient receive adjuvant gemcitabine six month . Patients randomized arm B undergo surgery receive adjuvant treatment arm A . The primary study-endpoint recurrence-free survival . Tumor recurrence determine computed tomography define protocol . - Trial medicinal product</brief_summary>
	<brief_title>Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy Resectable Pancreatic Cancer</brief_title>
	<detailed_description>Due improvement recurrence-free overall survival adjuvant chemotherapy , surgery follow adjuvant chemotherapy currently consider standard treatment resectable pancreatic cancer . However , significant proportion ( &gt; 25 % ) patient receive adjuvant treatment due morbidity pancreas surgery . Neoadjuvant ( preoperative ) chemotherapy appear particularly attractive since applied patient result significant histological tumor response median survival superior adjuvant chemotherapy recent prospective phase II trial . The aim study determine role neoadjuvant chemotherapy patient resectable pancreatic cancer.Eligible patient randomize : arm A : neoadjuvant chemotherapy + resection + adjuvant chemotherapy arm B : resection + adjuvant chemotherapy Neoadjuvant chemotherapy consist gemcitabine ( 1000mg/m2 ) oxaliplatin ( 100mg/m2 ) day 1 , 15 , 29 43 , adjuvant chemotherapy base gemcitabine 1000mg/m2 6 month . If restaging protocol excludes distant metastasis , diagnostic laparoscopy perform , follow Whipple operation absence distant metastasis . The primary study end-point recurrence-free survival study inclusion , define interval date write informed consent recurrence . Secondary end-points overall survival surgical complication rate . Interim analyse perform inclusion 100 200 patient without interrupt patient accrual . An independent data monitoring committee review result interim analysis decide study cessation continuation . Patients followed-up accord protocol order assess tumor recurrence . Quality life assess QLQ-30 questionnaire EORTC study entry , neoadjuvant chemotherapy , start end adjuvant chemotherapy follow-up study visit . Representative histological sample review stored reference pathologist University Hospital Zurich . These sample also use determine histological response extent cytopathic effect . Furthermore , nutritional status assess patient prealbumin serum level study entry prior surgery . Further translational research desire individually organize center .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Inclusion criterion : resectable adenocarcinoma pancreatic head ( require duodenopancreatectomy ) T13 , Nx , M0 ( UICC 6th version , 2002 ) infiltration portal vein ( &lt; 180° ) exclusion criterion cytologic histologic confirmation adenocarcinoma age &gt; 18 year write informed consent Exclusion criterion : contraindication Whipple procedure infiltration &gt; 180° portal vein abutment tumor superior mesenteric artery infiltration superior mesenteric artery celiac trunk chronic neuropathy &gt; grade 2 WHO performance score &gt; 2 uncorrectable cholestasis ( bilirubin &gt; 100mmol/l despite drainage attempt four week prior inclusion ) female patient child bear age use adequate contraception ( oral subcutaneous contraceptive , intrauterine pessary ( IUP ) , condom ) pregnant lactate woman mental organic disorder could interfere give informed consent receive treatment Second malignancy diagnose within past 5 year , except nonmelanomatous skin cancer noninvasive cervical cancer percutaneous biopsy primary tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>